What is Aclaris Therapeutics's market cap?

Aclaris Therapeutics (ACRS) has a market capitalization of $750.0M and trades on NASDAQ.

What is Aclaris Therapeutics's revenue and profitability?

Aclaris Therapeutics generated $8.4M in trailing twelve-month revenue with a net loss of $69.7M, representing a net margin of -832.6%. Gross margin stands at 76.3%, with free cash flow of -$52.3M. These figures are based on the Q1 2026 filing.

Who are Aclaris Therapeutics's competitors?

Aclaris Therapeutics's key competitors include Corvus Pharmaceuticals, Incyte, UpStream Bio, and others. These companies compete in similar markets and product categories.

Who does Aclaris Therapeutics partner with?

Aclaris Therapeutics's notable partners include Biosion, Inc., CTTQ, Pediatrix Therapeutics, Inc., and others.

What subsidiaries does Aclaris Therapeutics have?

Aclaris Therapeutics's subsidiaries include Confluence, Aclaris Life Sciences, Inc..

Where is Aclaris Therapeutics headquartered?

Aclaris Therapeutics is headquartered in United States of America and employs approximately 91 people. It has been publicly traded since 2015.

Aclaris Therapeutics

ACRS

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small and large molecule therapies for immuno-inflammatory diseases.

Market cap

$749.99M+353%

Revenue$8.4M-52.9%

Net income-$69.7M+46.5%

Free cash flow-$52.3M+5.4%

EPS (diluted)-$0.56+64.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$2.0MBeat by $674.3K EPS-$0.15Beat by $0.01

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$1.4M

EPS estimate-$0.16

Financials

Q1 2026

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation & ratios

Valuation

See full

Market cap$749.99M+353%

Enterprise value$723.32M+355%

P/S89.6×+78.8×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Segments

By product

See full

Dermatology Therapeutics$1.5M—

Contract Research$537.0K—

By segment

See full

Single Reportable$2.0M—

Competitors

By market cap

Incyte$23.7B+74.9%

AnaptysBio, Inc.$1.6B+103%

Corvus Pharmaceuticals$1.1B+203%

Avalo Therapeutics$1.0B+1,348%

Aclaris Therapeutics$750.0M+312%

Shattuck Labs, Inc.$672.4M+1,610%

Upstream Bio, Inc.$348.3M-54.8%

Kairos Pharma$6.6M-54.9%

By revenue growth

AnaptysBio, Inc.+108%

Upstream Bio, Inc.+44.7%

Incyte+26.9%

Aclaris Therapeutics-52.9%

Shattuck Labs, Inc.-78.3%

By net margin

Incyte27.71%+8.7pp

AnaptysBio, Inc.-49.94%+80.0pp

Aclaris Therapeutics-832.58%-100pp

Upstream Bio, Inc.-4,718.96%-1,270pp

Shattuck Labs, Inc.-4,987.4%-3,454pp

Avalo Therapeutics-7,965.76%—

Profile

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small and large molecule therapies for immuno-inflammatory diseases. The company utilizes its proprietary KINect drug discovery platform to identify product candidates with high target affinity and specificity, including covalent inhibitors and multi-specific antibodies. Its primary value proposition lies in advancing a pipeline of investigational treatments for conditions such as atopic dermatitis, asthma, and other T cell-mediated autoimmune disorders.

Competitive position

A clinical-stage innovator utilizing a specialized kinase discovery platform to develop potential best-in-class treatments for high-need inflammatory indications.

GeographiesUnited States, Global

Customer segmentsBiopharmaceutical companies, Healthcare providers

Business modelResearch and Development, IP Licensing, Drug Discovery Platform

SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Academic research institutions, Third-party IP licensors

CustomersMajor pharmaceutical companies, Specialty biotechnology firms, Regional commercialization partners

CountryUnited States of America

Listed2015

Employees91.0

CEONeal S. Walker

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteaclaristx.com

FilingsSEC EDGAR

Ask your AI about Aclaris Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's market cap?: Aclaris Therapeutics (ACRS) has a market capitalization of $750.0M and trades on NASDAQ.
What is Aclaris Therapeutics's revenue and profitability?: Aclaris Therapeutics generated $8.4M in trailing twelve-month revenue with a net loss of $69.7M, representing a net margin of -832.6%. Gross margin stands at 76.3%, with free cash flow of -$52.3M. These figures are based on the Q1 2026 filing.
Who are Aclaris Therapeutics's competitors?: Aclaris Therapeutics's key competitors include Corvus Pharmaceuticals, Incyte, UpStream Bio, and others. These companies compete in similar markets and product categories.
Who does Aclaris Therapeutics partner with?: Aclaris Therapeutics's notable partners include Biosion, Inc., CTTQ, Pediatrix Therapeutics, Inc., and others.
What subsidiaries does Aclaris Therapeutics have?: Aclaris Therapeutics's subsidiaries include Confluence, Aclaris Life Sciences, Inc..
Where is Aclaris Therapeutics headquartered?: Aclaris Therapeutics is headquartered in United States of America and employs approximately 91 people. It has been publicly traded since 2015.